Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S285000
Reexamination Certificate
active
07989467
ABSTRACT:
The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromosome 17 (a form of Parkinson's disease), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain neuropathologies including Alzheimer's disease linked to a mutation in the Tau protein, muscle atorphy which affects the SMN (Survival of Motor Neuron) gene, depression linked to a serotonin splicing impairment, and certain cancers in which the global splicing process is affected (e.g. breast cancer, colon cancer and certain lymphomas), as well as viral diseases such as AIDS.
REFERENCES:
patent: 6162811 (2000-12-01), Guillonneau et al.
patent: 2002/0018768 (2002-02-01), Kerem
patent: 0 010 029 (1980-04-01), None
patent: 0 317 416 (1989-05-01), None
patent: 0394112 (1990-10-01), None
patent: 2387229 (1978-11-01), None
patent: 2485537 (1981-12-01), None
patent: 2627493 (1989-08-01), None
patent: 2 665 162 (1992-01-01), None
patent: 5-310736 (1993-11-01), None
patent: 92/09602 (1992-06-01), None
patent: 01/66129 (2001-09-01), None
Chermann et al., 1978, CAS: 89:36630.
Tazi J et al: “DNA topoisomerase I: customs officer at the border between DNAand RNA worlds?” Journal of Molecular Medicine (Berlin, Germany) Nov.-Dec. 1997 vol. 75, No. 11-12, Nov. 1997, pp. 786-800.
Poddevin B et al: “Dual Topoisomerase I and II Inhibition by Intoplicine (RP-60475), A New Antitumor Agent in Early Clinical Trials” Molecular Pharmacology, Baltimore, MD, US, vol. 44, No. 4, Oct. 1, 1993, pp. 767-774.
Pilch B et al: “Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506” Cancer Research Sep. 15, 2001 United States, vol. 61, No. 18, Sep. 15, 2001, pp. 6876-6884.
Snyder A L et al: “Inhibition of the Processing of Ribosomal Precursor RNA by Ntercalating Agents” Journal of Molecular Biology, vol. 58, No. 2, 1971, pp. 555-565.
Kennedy G D et al: “Preparation and Nucleic Acid Binding of Ellipticine Derivatives” Heterocyclic Communications, Freund Publishing House, Tel Aviv, IL, vol. 2, No. 2, 1996, pp. 125-128.
Peng Yanhua et al: “Rescue of mutant p53 transcription function by ellipticine.” Oncogene, vol. 22, No. 29, Jul. 17, 2003, pp. 4478-4487.
Kansal V K et al: “The Biogenetic Synthetic and Biochemical Aspects of Ellipticine an Antitumor Alkaloid” Tetrahedron, vol. 42, No. 9, 1986, pp. 2389-2408.
Ohashi M et al: “Ellipticine and related anticancer agents” Expert Opinion on Therapeutic Patents 1996 United Kingdom, vol. 6, No. 12, 1996, pp. 1285-1294.
Pindur et al., “Antitumor active drugs as intercalators of deooxyribonucleic acid molecular models of intercalaton complexes”, Journal of Chemical Education, vol. 70, No. 4, (1993).
Hagg et al, Induction of Endoplasmic Reticulum stress by Elliptiicine Plant Alkaloids, Molecular Cancer Therapeutics, 3(4);489-497 (2004).
Sharp, P.A. (1994). Split genes and RNA splicing. Cell 77, 805-815).
Manley, J.L. and Tacke, R. (1996). SR proteins and splicing control. Genes Dev. 10, 1569-1579.
Graveley, B.R. Sorting out the complexity of SR protein functions. RNA.2000. 6, 1197-1211.
Wang, H.Y. et al., SC35 plays a role in T cell development and alternative splicing of CD45. Mol.Cell 2001.7, 331-342.
Ewing, B. and Green, P. Analysis of expressed sequence tags indicates 35,000 human genes. Nat.Genet.2000. 25, 232-234.
Cartegni, L. et al., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat.Rev. Genet.2002. 3, 285-298.
Nissim-Rafinia, M. et al., Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum.Mol.Genet.2000. 9, 1771-1778.
Sazani, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol.2002. 20, 1228-1233.
Cartegni, L. et al., Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat.Struct. Bio1.2003. 10, 120-125.
Andreassi, C. et al., Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum.Mol.Genet.2001.10, 2841-2849.
Liu, X et al., Partial correction of endogenous DeltaF508 CFTR in human cystic . fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat.Biotechnol. 2002. 20, 47-52.
Uekama, K. et al., Cyclodextrins in drug carrier systems. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 1-40.
Prochiantz, A., Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr.Opin.Neurobiol. 1996. 6, 629-634.
et Vives, E. et al., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J.Biol.Chem. 1997. 272, 16010-16017.
Douglas, S.J. et al., Nanoparticles in drug delivery. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 233-261 Gregoriadis, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.
Black, D.L., Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu.Rev.Biochem.2003. 72,291-336.
Gregoriadis, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.
Hofmann, Y. et al., Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc.Natl.Acad.Sci.U.S.A.2000. 97, 9618-9623.
Sazani, P. and Kole, R. Modulation of alternative splicing by antisense oligonucleotides. Prog.Mol.Subcell.Biol.2003. 31, 217-239.
Caputi et al., 2004. A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression. J. Virol. 78: 6517-26.
Pongoski et al., 2002. Positive and negative modulation of human immunodeficiency virus type 1 Rev function by cis and trans regulators of viral RNA splicing. J. Virol. 76: 5108-20.
Folks et al., 1988. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Immunol., 140: 1117-1122.
Jacquenet et al., 2001, A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP. H. J. Biol. Chem. 276: 40464-75.
Chermann et al,. Current Chemotherapy: Proceedings of the 10th International Congress of Chemotherapy (vol. II), pp. 1200-1201 (1978).
Bisagni Emile
Grierson David
Jeanteur Philippe
Nguyen Chi Hung
Rivalle Christian
Centre National de la Recherche Scientifique "CNRS"
Institut Curie
Lerner David Littenberg Krumholz & Mentlik LLP
Shiao Rei-tsang
Universite Montpellier II
LandOfFree
Use of indole-derived compounds for the preparation of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of indole-derived compounds for the preparation of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of indole-derived compounds for the preparation of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697636